These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25480858)

  • 41. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
    Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
    Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.
    Dolezal O; Gabelic T; Horakova D; Bergsland N; Dwyer MG; Seidl Z; Krasensky J; Ramasamy DP; Vaneckova M; Havrdova E; Zivadinov R
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S42-8. PubMed ID: 24321154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.
    Battaglini M; Giorgio A; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    J Neurol Sci; 2009 Jul; 282(1-2):55-60. PubMed ID: 19286193
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis.
    Prosperini L; Gallo V; Petsas N; Borriello G; Pozzilli C
    Eur J Neurol; 2009 Nov; 16(11):1202-9. PubMed ID: 19538207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis T2-weighted MRI of the brain after the administration of gadopentetate dimeglumine.
    Taschner CA; Kirsch EC; Scheffler K; Wetzel SG; Schulte-Mönting J; Kappos L; Radü EW
    Magn Reson Imaging; 2005 Apr; 23(3):469-74. PubMed ID: 15862648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TI-relaxation time changes over five years in relapsing-remitting multiple sclerosis.
    Papadopoulos K; Tozer DJ; Fisniku L; Altmann DR; Davies G; Rashid W; Thompson AJ; Miller DH; Chard DT
    Mult Scler; 2010 Apr; 16(4):427-33. PubMed ID: 20086026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution of acute "black hole" lesions in patients with relapsing-remitting multiple sclerosis.
    Kostic D; Dincic E; Jovanovski A; Kostic S; Rancic N; Georgievski-Brkic B; Misovic M; Koprivsek K
    Acta Neurol Belg; 2023 Jun; 123(3):831-838. PubMed ID: 35397094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.
    Barkhof F; Scheltens P; Frequin ST; Nauta JJ; Tas MW; Valk J; Hommes OR
    AJR Am J Roentgenol; 1992 Nov; 159(5):1041-7. PubMed ID: 1414773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage.
    Nessler S; Boretius S; Stadelmann C; Bittner A; Merkler D; Hartung HP; Michaelis T; Brück W; Frahm J; Sommer N; Hemmer B
    Brain; 2007 Aug; 130(Pt 8):2186-98. PubMed ID: 17617655
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study.
    Guttmann CR; Rousset M; Roch JA; Hannoun S; Durand-Dubief F; Belaroussi B; Cavallari M; Rabilloud M; Sappey-Marinier D; Vukusic S; Cotton F
    Mult Scler; 2016 May; 22(6):761-9. PubMed ID: 26362901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cervical cord lesion load is associated with disability independently from atrophy in MS.
    Kearney H; Altmann DR; Samson RS; Yiannakas MC; Wheeler-Kingshott CA; Ciccarelli O; Miller DH
    Neurology; 2015 Jan; 84(4):367-73. PubMed ID: 25540312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis.
    Mostert JP; de Groot JC; Ramsaransing GS; Koch MW; De Keyser J
    Eur J Neurol; 2007 Nov; 14(11):1210-5. PubMed ID: 17956444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lesion distribution in children with clinically isolated syndromes.
    Ghassemi R; Antel SB; Narayanan S; Francis SJ; Bar-Or A; Sadovnick AD; Banwell B; Arnold DL;
    Ann Neurol; 2008 Mar; 63(3):401-5. PubMed ID: 18306242
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 7T MRI Visualization of Cortical Lesions in Adolescents and Young Adults with Pediatric-Onset Multiple Sclerosis.
    Datta R; Sethi V; Ly S; Waldman AT; Narula S; Dewey BE; Sati P; Reich D; Banwell B
    J Neuroimaging; 2017 Sep; 27(5):447-452. PubMed ID: 28796432
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MRI time series modeling of MS lesion development.
    Meier DS; Guttmann CR
    Neuroimage; 2006 Aug; 32(2):531-7. PubMed ID: 16806979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.
    Combès B; Kerbrat A; Ferré JC; Callot V; Maranzano J; Badji A; Le Page E; Labauge P; Ayrignac X; Carra Dallière C; de Champfleur NM; Pelletier J; Maarouf A; de Seze J; Collongues N; Brassat D; Durand-Dubief F; Barillot C; Bannier E; Edan G
    Mult Scler; 2019 Jul; 25(8):1113-1123. PubMed ID: 29909771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis.
    Ciccarelli O; Giugni E; Paolillo A; Mainero C; Gasperini C; Bastianello S; Pozzilli C
    Eur J Neurol; 1999 Jul; 6(4):455-9. PubMed ID: 10362899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peripheral nerve involvement in multiple sclerosis: Demonstration by magnetic resonance neurography.
    Jende JME; Hauck GH; Diem R; Weiler M; Heiland S; Wildemann B; Korporal-Kuhnke M; Wick W; Hayes JM; Pfaff J; Pham M; Bendszus M; Kollmer J
    Ann Neurol; 2017 Nov; 82(5):676-685. PubMed ID: 29023976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.